InnoCare Pharma Limited 9969.HK Stock
InnoCare Pharma Limited Price Chart
InnoCare Pharma Limited 9969.HK Financial and Trading Overview
| InnoCare Pharma Limited stock price | 4.75 HKD |
| Previous Close | 7.6 HKD |
| Open | 7.67 HKD |
| Bid | 7.87 HKD x N/A |
| Ask | 7.91 HKD x N/A |
| Day's Range | 7.67 - 8.38 HKD |
| 52 Week Range | 6.97 - 15.9 HKD |
| Volume | 9.75M HKD |
| Avg. Volume | 3.75M HKD |
| Market Cap | 13.96B HKD |
| Beta (5Y Monthly) | 1.106858 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4 HKD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.83 HKD |
9969.HK Valuation Measures
| Enterprise Value | 4.83B HKD |
| Trailing P/E | N/A |
| Forward P/E | -23.264706 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 20.060873 |
| Price/Book (mrq) | 1.8550657 |
| Enterprise Value/Revenue | 6.939 |
| Enterprise Value/EBITDA | -6.952 |
Trading Information
InnoCare Pharma Limited Stock Price History
| Beta (5Y Monthly) | 1.106858 |
| 52-Week Change | -36.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.9 HKD |
| 52 Week Low | 6.97 HKD |
| 50-Day Moving Average | 8.49 HKD |
| 200-Day Moving Average | 10.38 HKD |
9969.HK Share Statistics
| Avg. Volume (3 month) | 3.75M HKD |
| Avg. Daily Volume (10-Days) | 2.12M HKD |
| Shares Outstanding | 1.76B |
| Float | 922.81M |
| Short Ratio | N/A |
| % Held by Insiders | 32.65% |
| % Held by Institutions | 37.86% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -112.23% |
| Operating Margin (ttm) | -107.50% |
| Gross Margin | 77.33% |
| EBITDA Margin | -99.79% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | -11.90% |
Income Statement
| Revenue (ttm) | 695.67M HKD |
| Revenue Per Share (ttm) | 0.49 HKD |
| Quarterly Revenue Growth (yoy) | 59.00% |
| Gross Profit (ttm) | 482.01M HKD |
| EBITDA | -694283968 HKD |
| Net Income Avi to Common (ttm) | -780756928 HKD |
| Diluted EPS (ttm) | -0.66 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.54B HKD |
| Total Cash Per Share (mrq) | 4.84 HKD |
| Total Debt (mrq) | 321.79M HKD |
| Total Debt/Equity (mrq) | 4.25 HKD |
| Current Ratio (mrq) | 4.506 |
| Book Value Per Share (mrq) | 4.264 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -581501760 HKD |
| Levered Free Cash Flow (ttm) | N/A |
Profile of InnoCare Pharma Limited
| Country | Hong Kong |
| State | N/A |
| City | Beijing |
| Address | Building 8 |
| ZIP | 102206 |
| Phone | 86 10 6660 9999 |
| Website | https://www.innocarepharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 939 |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Q&A For InnoCare Pharma Limited Stock
What is a current 9969.HK stock price?
InnoCare Pharma Limited 9969.HK stock price today per share is 4.75 HKD.
How to purchase InnoCare Pharma Limited stock?
You can buy 9969.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for InnoCare Pharma Limited?
The stock symbol or ticker of InnoCare Pharma Limited is 9969.HK.
Which industry does the InnoCare Pharma Limited company belong to?
The InnoCare Pharma Limited industry is Biotechnology.
How many shares does InnoCare Pharma Limited have in circulation?
The max supply of InnoCare Pharma Limited shares is 1.98B.
What is InnoCare Pharma Limited Price to Earnings Ratio (PE Ratio)?
InnoCare Pharma Limited PE Ratio is now.
What was InnoCare Pharma Limited earnings per share over the trailing 12 months (TTM)?
InnoCare Pharma Limited EPS is -0.4 HKD over the trailing 12 months.
Which sector does the InnoCare Pharma Limited company belong to?
The InnoCare Pharma Limited sector is Healthcare.